Aditya Bardia, MD, MPH

Articles

How Ki67 Informs Use of Therapy in Early-Stage HR+ Breast Cancer

February 9th 2023

A broad look at the role of Ki67 expression in informing the selection of therapy for patients with early-stage HR+ breast cancer.

Best Practices for Molecular Testing in Early-Stage Breast Cancer

February 9th 2023

Expert panelists share their perspectives on best practices for molecular profiling in patients diagnosed with early-stage breast cancer.

Dr. Bardia on the FDA Approval of Sacituzumab Govitecan in HR+/HER2– Metastatic Breast Cancer

February 8th 2023

Aditya Bardia, MD, MPH, discusses the significance of the FDA approval of sacituzumab govitecan in patients with pretreated hormone receptor–positive, HER2-negative metastatic breast cancer and key data from the phase 3 TROPiCS-02 trial.

Dr. Bardia on the Ongoing Investigation of Oral SERDs in ER+/HER2- Breast Cancer

December 19th 2022

Aditya Bardia, MD, MPH, discusses the investigation of oral selective estrogen receptor degraders in patients with estrogen receptor-positive, HER2-negative metastatic breast cancer.

Dr. Bardia on Elacestrant in ER+/HER2– Metastatic Breast Cancer

December 8th 2022

Aditya Bardia, MD, MPH, discusses the use of elacestrant in patients with estrogen receptor–positive, HER2-negative metastatic breast cancer.

Future Treatment Strategies for Triple-Negative Breast Cancer

September 19th 2022

Closing out his discussion on the management of metastatic triple-negative breast cancer, Aditya Bardia, MD, MPH, considers future treatment strategies that may improve outcomes for patients.

First-Line Treatment for Metastatic TNBC: Pembrolizumab + Chemotherapy

September 19th 2022

Comprehensive insight on use of first-line pembrolizumab plus chemotherapy in patients diagnosed with metastatic TNBC based on results from the KEYNOTE-355 trial.

Patient Scenario: A 44-Year-Old Woman With Metastatic TNBC

September 13th 2022

Centering discussion on a patient scenario of metastatic TNBC, Aditya Bardia, MD, MPH, highlights the value of first-line chemoimmunotherapy as a treatment option.

A Brief Overview of Treatment Options for Triple-Negative Breast Cancer

September 13th 2022

Expert oncologist Aditya Bardia, MD, MPH, shares his perspective on mainstay treatment options for patients diagnosed with metastatic triple-negative breast cancer.

Promising Strategies for Assessing Risk and Detecting Recurrence Earlier

August 31st 2022

Dr. Bardia discusses promising biomarkers and strategies for helping assess risk and detect recurrence in breast cancer.

Technical and Logistical Challenges Concerning the use of ctDNA Monitoring

August 31st 2022

Experienced clinician shares insight on potential challenges in the use of ctDNA monitoring.

Practical Clinical Applications for ctDNA Assessment

August 31st 2022

Clinical pearls addressing the current and potential future applications of ctDNA in breast cancer monitoring strategies.

Data Review: ctDNA Monitoring in Patients with Breast Cancer

August 31st 2022

Dr. Bardia reviews data from the ASCO 2022 Annual Meeting, focusing on serial postoperative ctDNA monitoring for breast cancer recurrence.

Clinical Evidence Supporting the use of ctDNA to Detect Recurrence

August 31st 2022

A breast cancer expert provides a brief overview of clinical evidence supporting the use of ctDNA to detect recurrence.

Best Practices for Assessing Risk of Recurrence in Patients with Breast Cancer

August 31st 2022

Aditya Bardia, MD, MPH shares his approach to assessing breast cancer recurrence risk and monitoring patients during and after treatment.

Optimizing Management of HR+/HER2- BC: Future Directions in Care

August 15th 2022

Closing out their discussion on HR+, HER2- breast cancer, expert panelists share their excitement for further evolution in the treatment paradigm.

Novel Therapy for Relapsed/Refractory HR+ BC: IO Therapy and PARP Inhibition

August 15th 2022

Expert perspectives on trial results with both IO and PARP inhibitor therapy, respectively, in the setting of relapsed/refractory HR+/HER2- breast cancer.

Considerations for Use of ADCs in HER2-Low Breast Cancer

August 15th 2022

A brief discussion on the use of antibody drug conjugates in patients with relapsed/refractory breast cancer and HER2-low expression.

ADCs in HR+/HER2- Advanced BC: Results From TROPICS-02 and DESTINY-Breast04

August 8th 2022

Centering discussion on the TROPICS-02 and DESTINY-Breast04 trials, panelists consider the advent of antibody drug conjugates in relapsed/refractory HR+ breast cancer.

Second-Line Use of CDK4/6 Inhibitors in HR+ Breast Cancer

August 8th 2022

Shared insight on the potential role of CDK4/6 inhibitors in the second-line setting of relapsed/refractory HR+/HER2- breast cancer.